Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer

Moróte, Juan; Morin, Jean‐Frédéric; Orsola, Anna; Junquera, J.M. Abascal; Salvador, C.; Trilla, Enrique; Raventós, Carles X.; Rosell, L. Cecchini; Encabo, Gloria; Reventós, Jaume

doi:10.1016/j.urology.2006.11.002

Cited by 165 publications

(111 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2). 16 Numerous prospective longitudinal studies have confirmed that BMD generally decreases significantly at the spine and hip, particularly during the first year of ADT; reported BMD losses after only 1 year of ADT range up to 4.8% at the lumbar spine and 3.8% at total hip. 17 Systematic retrospective reviews have also shown the association between ADT and increased fracture risk.…”

Section: Who Is At Risk? Who Should Be Screened?mentioning

confidence: 97%

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Egerdie

Saad

2013

CUAJ

View full text Add to dashboard Cite

Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with nonmetastatic prostate cancer. All such patients should have their bone mineral density (BMD) monitored and be offered preventive measures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. Several agents, including bisphosphonates, are available (although this use is currently offlabel), and upcoming treatments, such as denosumab and toremifene, have shown promise in reducing fracture risk in these patients. RésuméL'ostéoporose et les fractures osseuses sont des complications souvent négligées du traitement antiandrogénique chez les hommes atteints d'un cancer de la prostate non métastatique. La teneur minérale des os de ces patients devrait être surveillée, et des mesures préventives, comme la prise de suppléments de calcium et de vitamine D, devraient être offertes. Les patients présentant une faible teneur minérale des os devraient se voir offrir un traitement approprié. Plusieurs agents, y compris des bisphosphonates, sont offerts sur le marché (quoique cette indication ne soit pas officiellement approuvée à l'heure actuelle), et des traitements en cours d'étude, comme le dénosumab et le torémifène, se sont révélés prometteurs dans la réduction du risque de fracture chez ces patients.

show abstract

Section: Who Is At Risk? Who Should Be Screened?mentioning

confidence: 97%

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Egerdie

Saad

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…The incidence rate of osteoporosis increases from 36 to 80% after 10 years of hormonal therapy, and after that, osteopenia or osteoporosis can be expected to develop in all treated individuals [31].…”

Section: Osteoporosismentioning

confidence: 99%

Systemic complications in the hormonal treatment of prostate and breast cancer

Jagielska

Poniatowska²,

Tałasiewicz³

et al. 2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Oncological treatment is often associated with a wide range of adverse effects. The article focuses on systemic complications that may occur during the hormonal therapy of prostate and breast cancer. Considering that current treatments are increasingly effective, the number of patients suffering from early and remote complications of cancer therapy can be expected to rise. Many undergo radical treatment and in this group in particular, close attention should be paid to the prevention, early diagnosis, and treatment of adverse effects. Hormonal disorders and their complications considerably affect the quality of life and life expectancy by upsetting general systemic homeostasis. NOWOTWORY J Oncol 2017; 67, 3: 206-214

show abstract

“…25 Baseline studies in patients with newly diagnosed PCa have shown a high prevalence (ranging from 60% to 80%) of osteopenia and osteoporosis, even without hormonal treatment. 26 One study 27 reported a 35% prevalence in hormone-naive patients; however, in pts undergoing ADT, the prevalence increased steadily, reaching 43% after 2 years, 60% after 6 years, and 81% after 10 or more years. In our study, 46.4% had osteopenia, while osteoporosis was present in only 11 patients (6.5%).…”

Section: Osteoporosis and Osteopeniamentioning

confidence: 99%

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Ots

García

Kavadoy

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer

Cited by 165 publications

References 25 publications

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options

Systemic complications in the hormonal treatment of prostate and breast cancer

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Contact Info

Product

Resources

About